Trials / Completed
CompletedNCT00667108
A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 784 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabapentin | Gabapentin 250 mg oral capsule 30 minutes prior to bedtime |
| DRUG | Gabapentin | Gabapentin 500 mg oral capsule 30 minutes prior to bedtime |
| DRUG | Placebo | Matched placebo 30 minutes prior to bedtime |
Timeline
- Start date
- 2004-10-01
- Completion
- 2005-01-01
- First posted
- 2008-04-25
- Last updated
- 2021-02-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00667108. Inclusion in this directory is not an endorsement.